secwatch.observer — SEC 8-K summary
======================================

Issuer:     Keros Therapeutics, Inc. (KROS)
CIK:        0001664710
Form:       8-K
Filed at:   2024-06-17T23:59:59+00:00
Accession:  0001664710-24-000058
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Keros CEO Seehra becomes Chair; Rovaldi promoted to President effective July 1
------------------------------------------------------------------------------

- CEO Jasbir Seehra appointed Chair of Board, effective July 1, 2024, succeeding Carl Gordon who remains director.
- Christopher Rovaldi promoted to President in addition to COO, effective July 1, 2024, replacing Seehra as President.
- Jean-Jacques Bienaimé appointed Lead Independent Director, effective July 1, with a new $25,000 annual retainer.
- Leadership changes come as Keros prepares for first registrational Phase 3 trial of elritercept (KER-050).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1664710/000166471024000058/0001664710-24-000058-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1664710/000166471024000058/kros-20240614.htm
  HTML page:      https://secwatch.observer/filing/0001664710-24-000058

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer